Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Tivic Health Systems ( (TIVC) ) has shared an update.
Tivic Health Systems has shown notable advancements in its commercial business and its entry into the vagus nerve stimulation (VNS) sector. The company launched ClearUP 2.0, improved customer engagement, and enhanced its supply chain and marketing strategies, achieving significant growth in gross margins. Tivic is focusing on non-invasive VNS, which offers a substantial market opportunity, and has demonstrated promising results in pilot studies. The company is expanding its intellectual property portfolio and aims to move into clinical trials in 2025, expecting these developments to drive long-term shareholder value.
More about Tivic Health Systems
Tivic Health is a commercial health tech company specializing in bioelectronic medicine. Its technology focuses on non-invasive stimulation of nerve structures to provide drug-free therapeutic solutions for chronic inflammatory conditions. Tivic Health’s flagship product, ClearUP, is a handheld bioelectronic sinus device that is FDA approved and commercially available.
YTD Price Performance: -88.11%
Average Trading Volume: 5,667,963
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.77M
See more insights into TIVC stock on TipRanks’ Stock Analysis page.
